WO2001087834A1 - Antagoniste de l'hormone de concentration de la melanine - Google Patents
Antagoniste de l'hormone de concentration de la melanine Download PDFInfo
- Publication number
- WO2001087834A1 WO2001087834A1 PCT/JP2001/004015 JP0104015W WO0187834A1 WO 2001087834 A1 WO2001087834 A1 WO 2001087834A1 JP 0104015 W JP0104015 W JP 0104015W WO 0187834 A1 WO0187834 A1 WO 0187834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituent
- group
- ring
- compound
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001256733A AU2001256733A1 (en) | 2000-05-16 | 2001-05-15 | Melanin-concentrating hormone antagonist |
EP01930132A EP1283199A4 (en) | 2000-05-16 | 2001-05-15 | MELANIN CONCENTRATION HORMONE ANTAGONIST |
US10/276,288 US7229986B2 (en) | 2000-05-16 | 2001-05-15 | Melanin-concentrating hormone antagonist |
CA002408913A CA2408913A1 (en) | 2000-05-16 | 2001-05-15 | Melanin-concentrating hormone antagonist |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-148647 | 2000-05-16 | ||
JP2000148647 | 2000-05-16 | ||
JP2001-116219 | 2001-04-13 | ||
JP2001116219 | 2001-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001087834A1 true WO2001087834A1 (fr) | 2001-11-22 |
Family
ID=26592253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/004015 WO2001087834A1 (fr) | 2000-05-16 | 2001-05-15 | Antagoniste de l'hormone de concentration de la melanine |
Country Status (5)
Cited By (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050041A1 (en) * | 2000-12-21 | 2002-06-27 | F. Hoffmann-La Roche Ag | Dihydroindole and tetrahydroquinoline derivatives |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US6664273B2 (en) | 2001-11-26 | 2003-12-16 | Schering Corporation | Piperidine based MCH antagonists for treatment of obesity and CNS disorders |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2004024702A1 (de) * | 2002-08-24 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue carbonsäureamid-verbindungen mit mch-antagonistischer wirkung, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
WO2004056369A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxo Group Limited | Benzo ‘ d!azepine derivatives for the treatment of neurological disorders |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
US6858619B2 (en) | 2001-05-04 | 2005-02-22 | Amgen Inc. | Fused heterocyclic compounds |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
WO2005040824A2 (en) * | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) |
WO2005041962A1 (en) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
US6906075B2 (en) | 2002-01-10 | 2005-06-14 | Neurogen Corp. | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
WO2005085200A1 (ja) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン誘導体 |
US6953801B2 (en) | 2001-05-22 | 2005-10-11 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US7067509B2 (en) | 2003-03-07 | 2006-06-27 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
WO2006129826A1 (ja) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
WO2006132440A1 (ja) | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | 固形製剤 |
US7160879B2 (en) | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
WO2007028135A2 (en) | 2005-09-01 | 2007-03-08 | Takeda Pharmaceutical Company Limited | Imidazopyridine compounds |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
WO2007055418A1 (ja) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | アザ置換スピロ誘導体 |
WO2007074884A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
US7253179B2 (en) | 2002-11-06 | 2007-08-07 | Amgen Inc. | Fused heterocyclic compounds |
WO2007119833A1 (ja) | 2006-04-14 | 2007-10-25 | Takeda Pharmaceutical Company Limited | 含窒素複素環化合物 |
US7304065B2 (en) | 2003-10-01 | 2007-12-04 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
WO2008001778A1 (fr) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Animal génétiquement modifié et son utilisation |
WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
WO2008047821A1 (fr) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2008090944A1 (ja) | 2007-01-25 | 2008-07-31 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
WO2008102749A1 (ja) | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
WO2008143262A1 (ja) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
WO2009008487A1 (ja) | 2007-07-12 | 2009-01-15 | Takeda Pharmaceutical Company Limited | 被覆製剤 |
WO2009011451A1 (en) | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
WO2009051244A1 (ja) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2009057784A1 (ja) | 2007-11-01 | 2009-05-07 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2009087938A1 (ja) | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
WO2009110520A1 (ja) | 2008-03-05 | 2009-09-11 | 武田薬品工業株式会社 | 複素環化合物 |
WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
WO2009123194A1 (ja) | 2008-04-01 | 2009-10-08 | 武田薬品工業株式会社 | 複素環化合物 |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
WO2009128481A1 (ja) | 2008-04-16 | 2009-10-22 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2009145286A1 (ja) | 2008-05-30 | 2009-12-03 | 武田薬品工業株式会社 | 複素環化合物 |
WO2009154132A1 (ja) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | スピロジアミン-ジアリールケトオキシム誘導体 |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
WO2010016552A1 (ja) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 過敏性腸症候群治療薬 |
US7700625B2 (en) | 2005-04-13 | 2010-04-20 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP2010518001A (ja) * | 2007-02-02 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性のモジュレーターとしての化合物および組成物 |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
EP2248812A2 (en) | 2006-06-27 | 2010-11-10 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
EP2256115A1 (en) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
EP2308839A1 (en) | 2005-04-20 | 2011-04-13 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2332526A2 (en) | 2005-10-21 | 2011-06-15 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2508524A2 (en) | 2006-10-19 | 2012-10-10 | Takeda Pharmaceutical Company Limited | Indole compound |
WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
US8383619B2 (en) | 2008-04-11 | 2013-02-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8383647B2 (en) | 2009-01-30 | 2013-02-26 | Takeda Pharmaceutical Company Limited | Quinoline derivative |
WO2013054822A1 (en) | 2011-10-07 | 2013-04-18 | Takeda Pharmaceutical Company Limited | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US8653084B2 (en) | 2006-10-12 | 2014-02-18 | Astex Therapeutics Ltd. | Hydrobenzamide derivatives as inhibitors of Hsp90 |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014092100A1 (ja) | 2012-12-11 | 2014-06-19 | 武田薬品工業株式会社 | 複素環化合物 |
US8779132B2 (en) | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014163162A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014163161A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2015046482A1 (ja) | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015190613A1 (en) | 2014-06-09 | 2015-12-17 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2018147300A1 (ja) | 2017-02-08 | 2018-08-16 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002002530A1 (fr) * | 2000-07-04 | 2002-01-10 | Takeda Chemical Industries, Ltd. | Antagoniste de gpr14 |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
GB0229820D0 (en) * | 2002-12-20 | 2003-01-29 | Glaxo Group Ltd | Novel compounds |
WO2004069798A1 (ja) * | 2003-02-10 | 2004-08-19 | Banyu Pharmaceutical Co.,Ltd. | ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤 |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7605176B2 (en) | 2004-03-06 | 2009-10-20 | Boehringer Ingelheim International Gmbh | β-ketoamide compounds with MCH antagonistic activity |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
DE102004017934A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
ATE493973T1 (de) | 2004-06-04 | 2011-01-15 | Teva Pharma | Irbesartan enthaltende pharmazeutische zusammensetzung |
JP2008502644A (ja) * | 2004-06-18 | 2008-01-31 | グラクソ グループ リミテッド | ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
SI1828177T1 (sl) * | 2004-12-17 | 2009-02-28 | Lilly Co Eli | Novi antagonisti mch receptorja |
BRPI0519124A2 (pt) * | 2004-12-17 | 2008-12-23 | Lilly Co Eli | composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço |
TW200811158A (en) * | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Piperidine or pyrrolidine urea derivatives, their preparation and their therapeutic application |
FR2902790A1 (fr) * | 2006-06-27 | 2007-12-28 | Sanofi Aventis Sa | Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique |
TW200811170A (en) | 2006-06-27 | 2008-03-01 | Sanofi Aventis | Urea derivatives of tropane, their preparation and their therapeutic application |
EA018724B1 (ru) | 2006-08-07 | 2013-10-30 | Айронвуд Фармасьютикалз, Инк. | Соединения индола |
BRPI0722276A2 (pt) * | 2007-11-14 | 2014-04-22 | Amylin Pharmaceuticals Inc | Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
CN102099339A (zh) * | 2008-07-18 | 2011-06-15 | 武田药品工业株式会社 | 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途 |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
TW201141485A (en) * | 2010-01-08 | 2011-12-01 | Takeda Pharmaceutical | Compounds and their use |
WO2011083315A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Compounds and their use |
WO2011083316A1 (en) | 2010-01-08 | 2011-07-14 | Takeda Pharmaceutical Company Limited | Benzazepine derivatives for the treatment of central nervous system disorders |
AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
Citations (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1244593A (en) * | 1969-04-29 | 1971-09-02 | Bayer Ag | Sulphonyl-ureas and sulphonyl-semicarbazides which contain heterocyclic acyl radicals and have an antidiabetic effect |
DE2060720A1 (de) * | 1969-07-01 | 1972-06-22 | Thomae Gmbh Dr K | Neue Verfahren zur Herstellung von Sulfonylharnstoffen |
GB1313539A (en) * | 1969-07-01 | 1973-04-11 | Thomae Gmbh Dr K | Sulphonyl-ureas |
US4024128A (en) * | 1974-02-22 | 1977-05-17 | Hoffmann-La Roche Inc. | Benzazepinyl sulfonylureas and intermediates therefore |
US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
EP0002792A1 (en) * | 1978-01-03 | 1979-07-11 | Sandoz Ag | 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them |
US4242346A (en) * | 1979-12-19 | 1980-12-30 | Smithkline Corporation | Bis-2N-alkylene tetrahydroisoquinoline compounds |
EP0025864A1 (de) * | 1979-08-28 | 1981-04-01 | CASSELLA Aktiengesellschaft | Tetrahydrochinolinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Zubereitungen |
EP0038177A1 (en) * | 1980-04-14 | 1981-10-21 | Smithkline Beckman Corporation | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation |
JPS56147768A (en) * | 1980-04-19 | 1981-11-16 | Teikoku Chem Ind Corp Ltd | Preparation of indole derivative |
US4482560A (en) * | 1979-09-18 | 1984-11-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives, and antihistaminic agents containing the same |
EP0229623A2 (de) * | 1986-01-09 | 1987-07-22 | Hoechst Aktiengesellschaft | Diarylalkyl-substituierte Alkylamine, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel |
EP0230179A2 (fr) * | 1985-12-13 | 1987-07-29 | Roussel-Uclaf | Nouveaux dérivés du 4-morpholinyl 1H-indole, leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments, compositions les renfermant |
EP0263480A1 (de) * | 1986-10-06 | 1988-04-13 | CASSELLA Aktiengesellschaft | Tetrahydrochinolinderivate, ein Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Zubereitungen |
JPS63290821A (ja) * | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
EP0300725A1 (en) * | 1987-07-22 | 1989-01-25 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives as thromboxane A2 antagonists |
EP0343560A2 (en) * | 1988-05-23 | 1989-11-29 | Wakunaga Seiyaku Kabushiki Kaisha | Isoindoline derivative |
EP0383281A1 (en) * | 1989-02-14 | 1990-08-22 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
WO1991001724A1 (en) * | 1989-07-27 | 1991-02-21 | G.D. Searle & Co. | Renal-selective prodrugs for the treatment of hypertension |
EP0422666A2 (en) * | 1989-10-13 | 1991-04-17 | Abbott Laboratories | 6-Substituted-1,2,3,4-tetrahydroisoquinolines |
JPH03181478A (ja) * | 1989-12-08 | 1991-08-07 | Banyu Pharmaceut Co Ltd | ピリドンカルボン酸誘導体 |
WO1991016298A1 (en) * | 1990-04-20 | 1991-10-31 | Pfizer Inc | Antiinflammatory hydroxamic acids and n-hydroxyureas |
EP0457318A1 (en) * | 1990-05-17 | 1991-11-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Alpha-Oxopyrrolo[2,3-b]indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments |
WO1992003436A1 (en) * | 1990-08-14 | 1992-03-05 | Chugai Seiyaku Kabushiki Kaisha | Novel methotrexate derivative |
EP0476935A1 (en) * | 1990-09-18 | 1992-03-25 | Lilly Industries Limited | New indol and indoline derivatives |
JPH0495070A (ja) * | 1990-08-09 | 1992-03-27 | Toyama Chem Co Ltd | 1,2―エタンジオール誘導体およびその塩 |
EP0508723A1 (en) * | 1991-04-08 | 1992-10-14 | Merck & Co. Inc. | Angiotensin II antagonists incorporating an indole or dihydroindole |
EP0517357A1 (en) * | 1991-06-05 | 1992-12-09 | Merck & Co. Inc. | Angiotensin II antagonists incorporating a substituted indole or dihydroindole |
WO1993000335A1 (en) * | 1991-06-28 | 1993-01-07 | Pfizer Inc. | Tetrahydrobenzazepine derivatives which inhibit lipoxygenase |
EP0528369A2 (de) * | 1991-08-19 | 1993-02-24 | Dr. Karl Thomae GmbH | Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO1993012754A2 (en) * | 1991-12-20 | 1993-07-08 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
WO1993015077A1 (en) * | 1992-01-27 | 1993-08-05 | Chugai Seiyaku Kabushiki Kaisha | Methotrexate derivative |
EP0555824A1 (de) * | 1992-02-13 | 1993-08-18 | Dr. Karl Thomae GmbH | N-alpha-arylsulfonylierte Benzimidazolyl-alaninamid Derivate, diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung |
EP0560235A1 (en) * | 1992-03-09 | 1993-09-15 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic ketone derivatives, their production and use |
WO1993020065A1 (en) * | 1992-03-27 | 1993-10-14 | Kyoto Pharmaceutical Industries, Ltd. | Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor |
JPH0616558A (ja) * | 1992-02-13 | 1994-01-25 | Chugai Pharmaceut Co Ltd | 抗リウマチ剤 |
WO1994002459A1 (en) * | 1992-07-23 | 1994-02-03 | Pfizer Inc. | Indolinyl n-hydrozyurea and n-hydroxamic acid derivatives as lipoxygenase inhibitors |
EP0587180A2 (en) * | 1992-09-11 | 1994-03-16 | E.R. SQUIBB & SONS, INC. | Aryl urea (Thiourea) and cyanoguanidine derivatives |
WO1994008582A1 (en) * | 1992-10-16 | 1994-04-28 | Otsuka Pharmaceutical Co., Ltd. | Vasopressin antagonist and oxytocin antagonist |
EP0600675A1 (en) * | 1992-12-02 | 1994-06-08 | Kissei Pharmaceutical Co., Ltd. | Indoline compounds for the treatment of dysuria |
WO1994017035A1 (de) * | 1993-01-20 | 1994-08-04 | Dr. Karl Thomae Gmbh | Aminosäurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPH06239841A (ja) * | 1993-02-19 | 1994-08-30 | Eisai Co Ltd | 6,7−ジヒドロ−5H−シクロペンタ〔d〕ピリミジン誘導体 |
EP0634401A1 (en) * | 1993-07-16 | 1995-01-18 | American Cyanamid Company | MDR reversal agents |
WO1995013274A1 (en) * | 1993-11-08 | 1995-05-18 | Pfizer Limited | Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives |
EP0656350A1 (en) * | 1993-10-07 | 1995-06-07 | Bristol-Myers Squibb Company | Biaryl urea and related compounds |
WO1995017398A1 (en) * | 1993-12-21 | 1995-06-29 | Smithkline Beecham Plc | Indole, indoline and quinoline derivatives with 5ht1d (anti-depressive) activity |
WO1995020950A1 (en) * | 1994-02-03 | 1995-08-10 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
JPH07330726A (ja) * | 1994-06-01 | 1995-12-19 | Kissei Pharmaceut Co Ltd | インドール誘導体 |
JPH07330725A (ja) * | 1994-06-01 | 1995-12-19 | Kissei Pharmaceut Co Ltd | インドリン誘導体 |
WO1996001817A1 (en) * | 1994-05-07 | 1996-01-25 | Astra Aktiebolag | Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
WO1996006079A1 (en) * | 1994-08-23 | 1996-02-29 | Smithkline Beecham Plc | Biphenylamide derivatives as 5ht1d antagonists |
WO1996008491A1 (fr) * | 1994-09-16 | 1996-03-21 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de carbapeneme |
WO1996017606A1 (en) * | 1994-12-07 | 1996-06-13 | Bristol-Myers Squibb Company | Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage |
WO1996030014A1 (en) * | 1995-03-29 | 1996-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996035713A1 (en) * | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
WO1996038471A1 (en) * | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
WO1996039382A1 (en) * | 1995-06-06 | 1996-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives as 5-ht antagonists |
WO1997006158A1 (en) * | 1995-08-10 | 1997-02-20 | Astra Aktiebolag | Bicyclic amidine derivatives useful in therapy |
WO1997011069A1 (en) * | 1995-09-18 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as bradykinin antagonists |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
WO1997040051A1 (en) * | 1996-04-24 | 1997-10-30 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
WO1997043305A1 (en) * | 1996-05-14 | 1997-11-20 | Agouron Pharmaceuticals, Inc. | Inhibitors of picornavirus 3c proteases and methods for their use and preparation |
WO1997049695A1 (en) * | 1996-06-25 | 1997-12-31 | Smithkline Beecham P.L.C. | Sulfonamide derivatives as 5ht7 receptor antagonists |
WO1998006699A1 (en) * | 1996-08-14 | 1998-02-19 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
WO1998007719A1 (en) * | 1996-08-22 | 1998-02-26 | Dong Wha Pharm. Ind. Co., Ltd. | Arylsulfonylimidazolone derivatives as an antitumor agent |
US5767129A (en) * | 1995-08-24 | 1998-06-16 | Warner-Lambert Company | Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof |
WO1998025611A1 (en) * | 1996-12-13 | 1998-06-18 | Rhône-Poulenc Rorer Pharmaceuticals Inc. | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
WO1998029407A2 (en) * | 1996-12-27 | 1998-07-09 | Hoechst Marion Roussel, Inc. | N-(pyridinylamino)isoindolines for treating alzheimer's and depression |
WO1998046590A1 (en) * | 1997-04-17 | 1998-10-22 | Takeda Chemical Industries, Ltd. | Thermogenic composition and benzazepine thermogenics |
WO1998047876A1 (en) * | 1997-04-24 | 1998-10-29 | Akzo Nobel N.V. | Heterocyclic derivatives and their use as antithrombotic agents |
WO1998050346A2 (en) * | 1997-04-18 | 1998-11-12 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
WO1999000371A1 (de) * | 1997-06-26 | 1999-01-07 | Boehringer Ingelheim Pharma Kg | Phenylalkylderivate mit thrombinhemmender wirkung |
WO1999033798A1 (fr) * | 1997-12-25 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives heterocycliques azotes |
WO1999043652A1 (fr) * | 1998-02-27 | 1999-09-02 | Kissei Pharmaceutical Co., Ltd. | Derives de l'indole et compositions medicales les renfermant |
WO1999050237A1 (fr) * | 1998-03-30 | 1999-10-07 | Hiroyoshi Hidaka | Derives de sulfonamides et medicaments contenant ces derives en tant que principe actif |
WO1999062904A1 (en) * | 1998-06-03 | 1999-12-09 | Aventis Pharmaceuticals Products Inc. | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
JP2000016984A (ja) * | 1998-03-05 | 2000-01-18 | Pfizer Inc | デルタオピオイドアゴニストとしての化合物 |
WO2000012074A2 (en) * | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
WO2000015612A1 (en) * | 1998-08-26 | 2000-03-23 | Aventis Pharma Limited | Aza-bicycles which modulate the inhibition of cell adhesion |
WO2000017190A2 (fr) * | 1998-09-23 | 2000-03-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
WO2000021951A1 (en) * | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
WO2000023437A1 (fr) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant |
WO2000042036A1 (de) * | 1999-01-12 | 2000-07-20 | Basf Aktiengesellschaft | Triazolverbindungen mit dopamin-d3-rezeptoraffinität |
WO2000064866A1 (en) * | 1999-04-24 | 2000-11-02 | Astrazeneca Ab | Diphenylurea derivatives |
JP2000321732A (ja) * | 1999-05-07 | 2000-11-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料および画像形成方法 |
JP2000321736A (ja) * | 1999-05-07 | 2000-11-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料および画像形成方法 |
WO2000076970A2 (en) * | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
WO2000076966A2 (de) * | 1999-06-16 | 2000-12-21 | Bayer Aktiengesellschaft | Indolinylamidderivate und deren verwendung als antivirale arzneimittel |
WO2001005784A1 (en) * | 1999-07-16 | 2001-01-25 | Bristol-Myers Squibb Pharma Company | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS |
WO2001007412A1 (de) * | 1999-07-21 | 2001-02-01 | Bayer Aktiengesellschaft | Antivirale tetrahydroisichinolinsulfonamide |
WO2001012600A1 (en) * | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
WO2001021598A1 (en) * | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
WO2001021169A1 (fr) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone de concentration de la melanine |
WO2001032626A1 (en) * | 1999-11-05 | 2001-05-10 | Smithkline Beecham P.L.C. | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
WO2001044226A1 (en) * | 1999-12-14 | 2001-06-21 | Tularik Limited | Serine protease inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4170654A (en) | 1976-02-13 | 1979-10-09 | Merck & Co., Inc. | Antihypertensive compositions containing N-heterocyclicalanines and α- |
US4160835A (en) | 1976-11-19 | 1979-07-10 | Merck & Co., Inc. | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid |
JPS5465184A (en) | 1977-11-02 | 1979-05-25 | Sony Corp | Production of oxidizing agent |
GB2083392A (en) | 1980-09-08 | 1982-03-24 | Graham Douglas Ian | Wrench with rapid rotation facility |
US5280032A (en) | 1989-02-14 | 1994-01-18 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
GR1001322B (el) | 1990-04-06 | 1993-08-31 | Panagiotis Anagnostopoulos | Μηχανισμος μηχανων καμψης συρματος σε τρεις διαστασεις. |
US5264587A (en) | 1990-05-17 | 1993-11-23 | Hoechst-Roussel Pharmaceuticals Incorporated | Method of preparing α-oxopyrrolo[2,3-b]indole acetic acids and derivatives |
US5173497A (en) | 1990-05-17 | 1992-12-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Alpha-oxopyrrolo[2,3-B]indole acetic acids, esters, amides and related analogs |
US5462934A (en) | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
US5538973A (en) | 1992-03-27 | 1996-07-23 | Kyoto Pharmaceutical Industries, Ltd. | Imidazole derivative, pharmaceutical use thereof, and intermediate therefor |
US5541218A (en) | 1992-07-23 | 1996-07-30 | Pfizer Inc. | Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors |
JP2913082B2 (ja) | 1992-10-16 | 1999-06-28 | 大塚製薬株式会社 | バソプレシン拮抗剤及びオキシトシン拮抗剤 |
TW242557B (US07229986-20070612-C00045.png) * | 1993-02-18 | 1995-03-11 | Ciba Geigy | |
US6143791A (en) | 1994-02-03 | 2000-11-07 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
US5856530A (en) | 1996-05-14 | 1999-01-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
US6004977A (en) | 1996-12-27 | 1999-12-21 | Hoechst Marion Roussel, Inc. | N-(pyridinylamino) isoindolines and related compounds |
-
2001
- 2001-05-15 CA CA002408913A patent/CA2408913A1/en not_active Abandoned
- 2001-05-15 AU AU2001256733A patent/AU2001256733A1/en not_active Abandoned
- 2001-05-15 US US10/276,288 patent/US7229986B2/en not_active Expired - Fee Related
- 2001-05-15 EP EP01930132A patent/EP1283199A4/en not_active Withdrawn
- 2001-05-15 WO PCT/JP2001/004015 patent/WO2001087834A1/ja active Application Filing
Patent Citations (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1244593A (en) * | 1969-04-29 | 1971-09-02 | Bayer Ag | Sulphonyl-ureas and sulphonyl-semicarbazides which contain heterocyclic acyl radicals and have an antidiabetic effect |
DE2060720A1 (de) * | 1969-07-01 | 1972-06-22 | Thomae Gmbh Dr K | Neue Verfahren zur Herstellung von Sulfonylharnstoffen |
GB1313539A (en) * | 1969-07-01 | 1973-04-11 | Thomae Gmbh Dr K | Sulphonyl-ureas |
US4024128A (en) * | 1974-02-22 | 1977-05-17 | Hoffmann-La Roche Inc. | Benzazepinyl sulfonylureas and intermediates therefore |
US4156734A (en) * | 1976-02-13 | 1979-05-29 | Merck & Co., Inc. | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid |
EP0002792A1 (en) * | 1978-01-03 | 1979-07-11 | Sandoz Ag | 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them |
EP0025864A1 (de) * | 1979-08-28 | 1981-04-01 | CASSELLA Aktiengesellschaft | Tetrahydrochinolinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Zubereitungen |
US4482560A (en) * | 1979-09-18 | 1984-11-13 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives, and antihistaminic agents containing the same |
US4242346A (en) * | 1979-12-19 | 1980-12-30 | Smithkline Corporation | Bis-2N-alkylene tetrahydroisoquinoline compounds |
EP0038177A1 (en) * | 1980-04-14 | 1981-10-21 | Smithkline Beckman Corporation | Antiallergic imidodisulfamides, pharmaceutical compositions containing them and process for their preparation |
JPS56147768A (en) * | 1980-04-19 | 1981-11-16 | Teikoku Chem Ind Corp Ltd | Preparation of indole derivative |
EP0230179A2 (fr) * | 1985-12-13 | 1987-07-29 | Roussel-Uclaf | Nouveaux dérivés du 4-morpholinyl 1H-indole, leurs sels, procédé et intermédiaires de préparation, application à titre de médicaments, compositions les renfermant |
EP0229623A2 (de) * | 1986-01-09 | 1987-07-22 | Hoechst Aktiengesellschaft | Diarylalkyl-substituierte Alkylamine, Verfahren zu ihrer Herstellung, ihre Verwendung sowie sie enthaltende Arzneimittel |
EP0263480A1 (de) * | 1986-10-06 | 1988-04-13 | CASSELLA Aktiengesellschaft | Tetrahydrochinolinderivate, ein Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Zubereitungen |
JPS63290821A (ja) * | 1987-05-25 | 1988-11-28 | Otsuka Pharmaceut Co Ltd | 抗不整脈剤 |
EP0300725A1 (en) * | 1987-07-22 | 1989-01-25 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives as thromboxane A2 antagonists |
EP0343560A2 (en) * | 1988-05-23 | 1989-11-29 | Wakunaga Seiyaku Kabushiki Kaisha | Isoindoline derivative |
EP0383281A1 (en) * | 1989-02-14 | 1990-08-22 | Toyama Chemical Co., Ltd. | 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same |
WO1991001724A1 (en) * | 1989-07-27 | 1991-02-21 | G.D. Searle & Co. | Renal-selective prodrugs for the treatment of hypertension |
EP0422666A2 (en) * | 1989-10-13 | 1991-04-17 | Abbott Laboratories | 6-Substituted-1,2,3,4-tetrahydroisoquinolines |
JPH03181478A (ja) * | 1989-12-08 | 1991-08-07 | Banyu Pharmaceut Co Ltd | ピリドンカルボン酸誘導体 |
WO1991016298A1 (en) * | 1990-04-20 | 1991-10-31 | Pfizer Inc | Antiinflammatory hydroxamic acids and n-hydroxyureas |
US5256789A (en) * | 1990-04-20 | 1993-10-26 | Pfizer Inc. | Antiinflammatory hydroxamic acids and N-hydroxyureas |
EP0457318A1 (en) * | 1990-05-17 | 1991-11-21 | Hoechst-Roussel Pharmaceuticals Incorporated | Alpha-Oxopyrrolo[2,3-b]indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments |
JPH0495070A (ja) * | 1990-08-09 | 1992-03-27 | Toyama Chem Co Ltd | 1,2―エタンジオール誘導体およびその塩 |
WO1992003436A1 (en) * | 1990-08-14 | 1992-03-05 | Chugai Seiyaku Kabushiki Kaisha | Novel methotrexate derivative |
EP0476935A1 (en) * | 1990-09-18 | 1992-03-25 | Lilly Industries Limited | New indol and indoline derivatives |
EP0508723A1 (en) * | 1991-04-08 | 1992-10-14 | Merck & Co. Inc. | Angiotensin II antagonists incorporating an indole or dihydroindole |
EP0517357A1 (en) * | 1991-06-05 | 1992-12-09 | Merck & Co. Inc. | Angiotensin II antagonists incorporating a substituted indole or dihydroindole |
WO1993000335A1 (en) * | 1991-06-28 | 1993-01-07 | Pfizer Inc. | Tetrahydrobenzazepine derivatives which inhibit lipoxygenase |
EP0528369A2 (de) * | 1991-08-19 | 1993-02-24 | Dr. Karl Thomae GmbH | Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
WO1993012754A2 (en) * | 1991-12-20 | 1993-07-08 | Abbott Laboratories | Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors |
WO1993015077A1 (en) * | 1992-01-27 | 1993-08-05 | Chugai Seiyaku Kabushiki Kaisha | Methotrexate derivative |
EP0555824A1 (de) * | 1992-02-13 | 1993-08-18 | Dr. Karl Thomae GmbH | N-alpha-arylsulfonylierte Benzimidazolyl-alaninamid Derivate, diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung |
JPH0616558A (ja) * | 1992-02-13 | 1994-01-25 | Chugai Pharmaceut Co Ltd | 抗リウマチ剤 |
EP0560235A1 (en) * | 1992-03-09 | 1993-09-15 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic ketone derivatives, their production and use |
WO1993020065A1 (en) * | 1992-03-27 | 1993-10-14 | Kyoto Pharmaceutical Industries, Ltd. | Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor |
WO1994002459A1 (en) * | 1992-07-23 | 1994-02-03 | Pfizer Inc. | Indolinyl n-hydrozyurea and n-hydroxamic acid derivatives as lipoxygenase inhibitors |
EP0587180A2 (en) * | 1992-09-11 | 1994-03-16 | E.R. SQUIBB & SONS, INC. | Aryl urea (Thiourea) and cyanoguanidine derivatives |
WO1994008582A1 (en) * | 1992-10-16 | 1994-04-28 | Otsuka Pharmaceutical Co., Ltd. | Vasopressin antagonist and oxytocin antagonist |
EP0600675A1 (en) * | 1992-12-02 | 1994-06-08 | Kissei Pharmaceutical Co., Ltd. | Indoline compounds for the treatment of dysuria |
WO1994017035A1 (de) * | 1993-01-20 | 1994-08-04 | Dr. Karl Thomae Gmbh | Aminosäurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
JPH06239841A (ja) * | 1993-02-19 | 1994-08-30 | Eisai Co Ltd | 6,7−ジヒドロ−5H−シクロペンタ〔d〕ピリミジン誘導体 |
EP0634401A1 (en) * | 1993-07-16 | 1995-01-18 | American Cyanamid Company | MDR reversal agents |
EP0656350A1 (en) * | 1993-10-07 | 1995-06-07 | Bristol-Myers Squibb Company | Biaryl urea and related compounds |
WO1995013274A1 (en) * | 1993-11-08 | 1995-05-18 | Pfizer Limited | Antithrombotic amidinophenylalanine and amidinopyridylalanine derivatives |
WO1995017398A1 (en) * | 1993-12-21 | 1995-06-29 | Smithkline Beecham Plc | Indole, indoline and quinoline derivatives with 5ht1d (anti-depressive) activity |
WO1995020950A1 (en) * | 1994-02-03 | 1995-08-10 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
WO1996001817A1 (en) * | 1994-05-07 | 1996-01-25 | Astra Aktiebolag | Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
JPH07330726A (ja) * | 1994-06-01 | 1995-12-19 | Kissei Pharmaceut Co Ltd | インドール誘導体 |
JPH07330725A (ja) * | 1994-06-01 | 1995-12-19 | Kissei Pharmaceut Co Ltd | インドリン誘導体 |
WO1996006079A1 (en) * | 1994-08-23 | 1996-02-29 | Smithkline Beecham Plc | Biphenylamide derivatives as 5ht1d antagonists |
WO1996008491A1 (fr) * | 1994-09-16 | 1996-03-21 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de carbapeneme |
WO1996017606A1 (en) * | 1994-12-07 | 1996-06-13 | Bristol-Myers Squibb Company | Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage |
WO1996030014A1 (en) * | 1995-03-29 | 1996-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1996035713A1 (en) * | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
WO1996038471A1 (en) * | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
WO1996039382A1 (en) * | 1995-06-06 | 1996-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Urea derivatives as 5-ht antagonists |
WO1997006158A1 (en) * | 1995-08-10 | 1997-02-20 | Astra Aktiebolag | Bicyclic amidine derivatives useful in therapy |
US5767129A (en) * | 1995-08-24 | 1998-06-16 | Warner-Lambert Company | Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof |
WO1997011069A1 (en) * | 1995-09-18 | 1997-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as bradykinin antagonists |
EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
WO1997040051A1 (en) * | 1996-04-24 | 1997-10-30 | Takeda Chemical Industries, Ltd. | Fused imidazopyridine derivatives as antihyperlipidemic agents |
WO1997043305A1 (en) * | 1996-05-14 | 1997-11-20 | Agouron Pharmaceuticals, Inc. | Inhibitors of picornavirus 3c proteases and methods for their use and preparation |
WO1997049695A1 (en) * | 1996-06-25 | 1997-12-31 | Smithkline Beecham P.L.C. | Sulfonamide derivatives as 5ht7 receptor antagonists |
WO1998006699A1 (en) * | 1996-08-14 | 1998-02-19 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
WO1998007719A1 (en) * | 1996-08-22 | 1998-02-26 | Dong Wha Pharm. Ind. Co., Ltd. | Arylsulfonylimidazolone derivatives as an antitumor agent |
WO1998025611A1 (en) * | 1996-12-13 | 1998-06-18 | Rhône-Poulenc Rorer Pharmaceuticals Inc. | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
WO1998029407A2 (en) * | 1996-12-27 | 1998-07-09 | Hoechst Marion Roussel, Inc. | N-(pyridinylamino)isoindolines for treating alzheimer's and depression |
WO1998046590A1 (en) * | 1997-04-17 | 1998-10-22 | Takeda Chemical Industries, Ltd. | Thermogenic composition and benzazepine thermogenics |
WO1998050346A2 (en) * | 1997-04-18 | 1998-11-12 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
WO1998047876A1 (en) * | 1997-04-24 | 1998-10-29 | Akzo Nobel N.V. | Heterocyclic derivatives and their use as antithrombotic agents |
WO1999000371A1 (de) * | 1997-06-26 | 1999-01-07 | Boehringer Ingelheim Pharma Kg | Phenylalkylderivate mit thrombinhemmender wirkung |
WO1999033798A1 (fr) * | 1997-12-25 | 1999-07-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives heterocycliques azotes |
WO1999043652A1 (fr) * | 1998-02-27 | 1999-09-02 | Kissei Pharmaceutical Co., Ltd. | Derives de l'indole et compositions medicales les renfermant |
JP2000016984A (ja) * | 1998-03-05 | 2000-01-18 | Pfizer Inc | デルタオピオイドアゴニストとしての化合物 |
WO1999050237A1 (fr) * | 1998-03-30 | 1999-10-07 | Hiroyoshi Hidaka | Derives de sulfonamides et medicaments contenant ces derives en tant que principe actif |
WO1999062904A1 (en) * | 1998-06-03 | 1999-12-09 | Aventis Pharmaceuticals Products Inc. | Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
WO2000015612A1 (en) * | 1998-08-26 | 2000-03-23 | Aventis Pharma Limited | Aza-bicycles which modulate the inhibition of cell adhesion |
WO2000012074A2 (en) * | 1998-08-28 | 2000-03-09 | Scios Inc. | Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase |
WO2000017190A2 (fr) * | 1998-09-23 | 2000-03-30 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
WO2000021951A1 (en) * | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
WO2000023437A1 (fr) * | 1998-10-16 | 2000-04-27 | Takeda Chemical Industries, Ltd. | Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant |
WO2000042036A1 (de) * | 1999-01-12 | 2000-07-20 | Basf Aktiengesellschaft | Triazolverbindungen mit dopamin-d3-rezeptoraffinität |
WO2000064866A1 (en) * | 1999-04-24 | 2000-11-02 | Astrazeneca Ab | Diphenylurea derivatives |
JP2000321732A (ja) * | 1999-05-07 | 2000-11-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料および画像形成方法 |
JP2000321736A (ja) * | 1999-05-07 | 2000-11-24 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料および画像形成方法 |
WO2000076970A2 (en) * | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
WO2000077027A2 (en) * | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
WO2000076966A2 (de) * | 1999-06-16 | 2000-12-21 | Bayer Aktiengesellschaft | Indolinylamidderivate und deren verwendung als antivirale arzneimittel |
WO2001005784A1 (en) * | 1999-07-16 | 2001-01-25 | Bristol-Myers Squibb Pharma Company | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS |
WO2001007412A1 (de) * | 1999-07-21 | 2001-02-01 | Bayer Aktiengesellschaft | Antivirale tetrahydroisichinolinsulfonamide |
WO2001012600A1 (en) * | 1999-08-12 | 2001-02-22 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
WO2001021169A1 (fr) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone de concentration de la melanine |
WO2001021598A1 (en) * | 1999-09-23 | 2001-03-29 | Astrazeneca Ab | Therapeutic quinazoline compounds |
WO2001032626A1 (en) * | 1999-11-05 | 2001-05-10 | Smithkline Beecham P.L.C. | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
WO2001044226A1 (en) * | 1999-12-14 | 2001-06-21 | Tularik Limited | Serine protease inhibitors |
Non-Patent Citations (2)
Title |
---|
See also references of EP1283199A4 * |
SHIV K. AGARWAL ET AL.: "Sect. B", INDIAN J. CHEM., vol. 26B, no. 7, 1987, pages 642 - 646, XP002944776 * |
Cited By (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6753336B2 (en) | 2000-07-06 | 2004-06-22 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US7323478B2 (en) | 2000-07-06 | 2008-01-29 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
US7102007B2 (en) | 2000-12-21 | 2006-09-05 | Hoffmann-La Roche Inc. | Dihydroindole and tetrahydroquinoline derivatives |
US6706751B2 (en) | 2000-12-21 | 2004-03-16 | Hoffman-La Roche Inc. | Dihydroindole and tetrahydroquinoline derivatives |
WO2002050041A1 (en) * | 2000-12-21 | 2002-06-27 | F. Hoffmann-La Roche Ag | Dihydroindole and tetrahydroquinoline derivatives |
US6809104B2 (en) | 2001-05-04 | 2004-10-26 | Tularik Inc. | Fused heterocyclic compounds |
US6858619B2 (en) | 2001-05-04 | 2005-02-22 | Amgen Inc. | Fused heterocyclic compounds |
US7125885B2 (en) | 2001-05-04 | 2006-10-24 | Amgen Inc. | Fused heterocyclic compounds |
US7081458B2 (en) | 2001-05-22 | 2006-07-25 | Neurogen Corp. | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US6953801B2 (en) | 2001-05-22 | 2005-10-11 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US6664273B2 (en) | 2001-11-26 | 2003-12-16 | Schering Corporation | Piperidine based MCH antagonists for treatment of obesity and CNS disorders |
US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
US6906075B2 (en) | 2002-01-10 | 2005-06-14 | Neurogen Corp. | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues |
US7160879B2 (en) | 2002-01-10 | 2007-01-09 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2004024702A1 (de) * | 2002-08-24 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue carbonsäureamid-verbindungen mit mch-antagonistischer wirkung, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US7253179B2 (en) | 2002-11-06 | 2007-08-07 | Amgen Inc. | Fused heterocyclic compounds |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
KR100765027B1 (ko) * | 2002-12-20 | 2007-10-09 | 글락소 그룹 리미티드 | 신경 장애 치료용 벤즈아제핀 유도체 |
JP2010248239A (ja) * | 2002-12-20 | 2010-11-04 | Glaxo Group Ltd | 神経系の障害の治療用のベンゾジアゼピン誘導体 |
JP2006512412A (ja) * | 2002-12-20 | 2006-04-13 | グラクソ グループ リミテッド | 神経系の障害の治療用のベンゾジアゼピン誘導体 |
US7704994B2 (en) | 2002-12-20 | 2010-04-27 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
US7696193B2 (en) | 2002-12-20 | 2010-04-13 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
EP2186516A1 (en) | 2002-12-20 | 2010-05-19 | Glaxo Group Limited | Novel benzazepine derivative |
US7799773B2 (en) | 2002-12-20 | 2010-09-21 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
AU2003294909B2 (en) * | 2002-12-20 | 2007-05-17 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
EP2133340A1 (en) | 2002-12-20 | 2009-12-16 | Glaxo Group Limited | Novel benzazepine derivatives |
KR100897642B1 (ko) | 2002-12-20 | 2009-05-14 | 글락소 그룹 리미티드 | 신경 장애 치료용 벤즈아제핀 유도체 |
US8207331B2 (en) | 2002-12-20 | 2012-06-26 | Glaxo Group Limited | Benzazepine derivatives for the treatment of neurological disorders |
WO2004056369A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxo Group Limited | Benzo ‘ d!azepine derivatives for the treatment of neurological disorders |
US7067509B2 (en) | 2003-03-07 | 2006-06-27 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
WO2005028438A1 (ja) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
US7304065B2 (en) | 2003-10-01 | 2007-12-04 | The Procter & Gamble Company | Melanin concentrating hormone antagonists |
WO2005040824A3 (en) * | 2003-10-24 | 2005-06-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) |
WO2005040824A2 (en) * | 2003-10-24 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) |
WO2005041962A1 (en) | 2003-10-31 | 2005-05-12 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
WO2005085200A1 (ja) * | 2004-03-05 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン誘導体 |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2253315A1 (en) | 2004-03-30 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
EP2286838A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
EP2286840A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2286837A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and obesity related diseases |
EP2286839A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US8530469B2 (en) | 2005-04-13 | 2013-09-10 | Astex Therapeutics Ltd. | Therapeutic combinations of hydroxybenzamide derivatives as inhibitors of HSP90 |
US7700625B2 (en) | 2005-04-13 | 2010-04-20 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 |
US8101648B2 (en) | 2005-04-13 | 2012-01-24 | Astex Therapeutics, Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 |
US8816087B2 (en) | 2005-04-13 | 2014-08-26 | Astex Therapeutics Limited | Hydroxybenzamide derivatives and their use as inhibitors of Hsp90 |
US9914719B2 (en) | 2005-04-13 | 2018-03-13 | Astex Therapeutics Ltd. | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 |
EP2308839A1 (en) | 2005-04-20 | 2011-04-13 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
WO2006129826A1 (ja) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | 新規ピペリジン誘導体 |
WO2006132440A1 (ja) | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | 固形製剤 |
WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
WO2007028135A2 (en) | 2005-09-01 | 2007-03-08 | Takeda Pharmaceutical Company Limited | Imidazopyridine compounds |
WO2007029847A1 (ja) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | 二環性芳香族置換ピリドン誘導体 |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
EP2332526A2 (en) | 2005-10-21 | 2011-06-15 | Novartis AG | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
WO2007055418A1 (ja) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | アザ置換スピロ誘導体 |
WO2007074884A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 糖尿病治療剤 |
US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
US8106057B2 (en) | 2006-03-01 | 2012-01-31 | Astex Therapeutics, Ltd. | Dihydroxyphenyl isoindolylmethanones |
WO2007119833A1 (ja) | 2006-04-14 | 2007-10-25 | Takeda Pharmaceutical Company Limited | 含窒素複素環化合物 |
EP2743268A2 (en) | 2006-06-27 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
WO2008001778A1 (fr) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Animal génétiquement modifié et son utilisation |
EP2248812A2 (en) | 2006-06-27 | 2010-11-10 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
EP2431367A2 (en) | 2006-06-27 | 2012-03-21 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds as GPR40 receptor modulators |
WO2008016131A1 (fr) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
US9730912B2 (en) | 2006-10-12 | 2017-08-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
US8277807B2 (en) | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
US8653084B2 (en) | 2006-10-12 | 2014-02-18 | Astex Therapeutics Ltd. | Hydrobenzamide derivatives as inhibitors of Hsp90 |
US8779132B2 (en) | 2006-10-12 | 2014-07-15 | Astex Therapeutics Limited | Pharmaceutical compounds |
US9428439B2 (en) | 2006-10-12 | 2016-08-30 | Astex Therapeutics Ltd. | Hydrobenzamide derivatives as inhibitors of Hsp90 |
US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
WO2008047821A1 (fr) | 2006-10-18 | 2008-04-24 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique fusionné |
EP2508524A2 (en) | 2006-10-19 | 2012-10-10 | Takeda Pharmaceutical Company Limited | Indole compound |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
EP2256115A1 (en) | 2006-11-24 | 2010-12-01 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound and use thereof |
WO2008090944A1 (ja) | 2007-01-25 | 2008-07-31 | Takeda Pharmaceutical Company Limited | スピロ環化合物 |
WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
JP2010518001A (ja) * | 2007-02-02 | 2010-05-27 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性のモジュレーターとしての化合物および組成物 |
WO2008102749A1 (ja) | 2007-02-20 | 2008-08-28 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
WO2008136428A1 (ja) | 2007-04-27 | 2008-11-13 | Takeda Pharmaceutical Company Limited | 含窒素5員複素環化合物 |
WO2008143262A1 (ja) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
EP2253630A1 (en) | 2007-05-21 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009008487A1 (ja) | 2007-07-12 | 2009-01-15 | Takeda Pharmaceutical Company Limited | 被覆製剤 |
WO2009011451A1 (en) | 2007-07-19 | 2009-01-22 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
US8900638B2 (en) | 2007-07-19 | 2014-12-02 | Takeda Pharmaceutical Company Limited | Solid preparation comprising alogliptin and metformin hydrochloride |
WO2009051244A1 (ja) | 2007-10-18 | 2009-04-23 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2009057784A1 (ja) | 2007-11-01 | 2009-05-07 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
WO2009087938A1 (ja) | 2008-01-10 | 2009-07-16 | Takeda Pharmaceutical Company Limited | カプセル製剤 |
EP2455071A1 (en) | 2008-01-10 | 2012-05-23 | Takeda Pharmaceutical Company Limited | Capsule Formulation |
WO2009110520A1 (ja) | 2008-03-05 | 2009-09-11 | 武田薬品工業株式会社 | 複素環化合物 |
WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
WO2009119726A1 (ja) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
WO2009123194A1 (ja) | 2008-04-01 | 2009-10-08 | 武田薬品工業株式会社 | 複素環化合物 |
WO2009123316A1 (ja) | 2008-04-04 | 2009-10-08 | 武田薬品工業株式会社 | 複素環誘導体及びその用途 |
US8664218B2 (en) | 2008-04-11 | 2014-03-04 | Astex Therapeutics Ltd. | Pharmaceutical compounds |
US8383619B2 (en) | 2008-04-11 | 2013-02-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2009128481A1 (ja) | 2008-04-16 | 2009-10-22 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
WO2009145286A1 (ja) | 2008-05-30 | 2009-12-03 | 武田薬品工業株式会社 | 複素環化合物 |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009154132A1 (ja) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | スピロジアミン-ジアリールケトオキシム誘導体 |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
WO2010016552A1 (ja) | 2008-08-07 | 2010-02-11 | 武田薬品工業株式会社 | 過敏性腸症候群治療薬 |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010050445A1 (ja) | 2008-10-27 | 2010-05-06 | 武田薬品工業株式会社 | 二環性化合物 |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US8383647B2 (en) | 2009-01-30 | 2013-02-26 | Takeda Pharmaceutical Company Limited | Quinoline derivative |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011136385A1 (en) | 2010-04-27 | 2011-11-03 | Takeda Pharmaceutical Company Limited | Bicyclic compound derivatives and their use as acc inhibitors. |
WO2012074126A1 (en) | 2010-11-30 | 2012-06-07 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013018929A1 (en) | 2011-08-04 | 2013-02-07 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
WO2013054822A1 (en) | 2011-10-07 | 2013-04-18 | Takeda Pharmaceutical Company Limited | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
WO2013061962A1 (ja) | 2011-10-24 | 2013-05-02 | 武田薬品工業株式会社 | 二環性化合物 |
WO2013125732A1 (en) | 2012-02-24 | 2013-08-29 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2013147026A1 (ja) | 2012-03-29 | 2013-10-03 | 武田薬品工業株式会社 | 芳香環化合物 |
WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014061676A1 (ja) | 2012-10-16 | 2014-04-24 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014092100A1 (ja) | 2012-12-11 | 2014-06-19 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014142363A1 (en) | 2013-03-14 | 2014-09-18 | Takeda Pharmaceutical Company Limited | Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014163162A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014163161A1 (ja) | 2013-04-04 | 2014-10-09 | 武田薬品工業株式会社 | 複素環化合物 |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015046482A1 (ja) | 2013-09-30 | 2015-04-02 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015190613A1 (en) | 2014-06-09 | 2015-12-17 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
US11254644B2 (en) | 2014-08-29 | 2022-02-22 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US10513499B2 (en) | 2014-08-29 | 2019-12-24 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2018147300A1 (ja) | 2017-02-08 | 2018-08-16 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
US7229986B2 (en) | 2007-06-12 |
EP1283199A1 (en) | 2003-02-12 |
EP1283199A4 (en) | 2003-12-17 |
CA2408913A1 (en) | 2001-11-22 |
AU2001256733A1 (en) | 2001-11-26 |
US20030158177A1 (en) | 2003-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001087834A1 (fr) | Antagoniste de l'hormone de concentration de la melanine | |
US7183415B2 (en) | Quinoline compound | |
US6930185B2 (en) | Melanin-concentrating hormone antagonist | |
WO2001025228A1 (fr) | Derives d'amines | |
WO2001021169A1 (fr) | Antagonistes de l'hormone de concentration de la melanine | |
US20070173498A1 (en) | Melanin concentrating hormone antagonist | |
WO2001087293A1 (fr) | Inhibiteurs de la ?-secretase | |
US20050245571A1 (en) | Amine derivative | |
WO2004072018A1 (ja) | アミン誘導体 | |
JP2002003370A (ja) | メラニン凝集ホルモン拮抗剤 | |
WO2000023420A1 (fr) | Derives d'amine aromatique, procede de preparation de ces derives et agents les contenant | |
JP2002371059A (ja) | メラニン凝集ホルモン拮抗剤 | |
US20060223826A1 (en) | Indole derivatives as somatostatin agonists or antagonists | |
WO2004011470A1 (ja) | フロイソキノリン誘導体およびその用途 | |
JP2002241274A (ja) | メラニン凝集ホルモン拮抗剤 | |
US10519105B2 (en) | KCNQ2-5 channel activator | |
JP4630555B2 (ja) | アミン誘導体 | |
JP2004059567A (ja) | キノリン化合物 | |
JP2004300133A (ja) | アミン誘導体 | |
JPH11180979A (ja) | 環状アミン誘導体 | |
WO2021189051A1 (en) | Androgen receptor regulation by small molecule enantiomers | |
US20230133119A1 (en) | Androgen receptor regulation by small molecule enantiomers | |
JP2002097138A (ja) | Mch拮抗剤 | |
JP2002348287A (ja) | アミン誘導体 | |
JP2003192682A (ja) | アミン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10276288 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2408913 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001930132 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001930132 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |